WO2020111167A1 - Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 - Google Patents
Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 Download PDFInfo
- Publication number
- WO2020111167A1 WO2020111167A1 PCT/JP2019/046505 JP2019046505W WO2020111167A1 WO 2020111167 A1 WO2020111167 A1 WO 2020111167A1 JP 2019046505 W JP2019046505 W JP 2019046505W WO 2020111167 A1 WO2020111167 A1 WO 2020111167A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- amino acid
- phb2
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the estrogen receptor (ER) activation regulatory molecule BIG3 interacts with the inhibitor PHB2 to induce constitutive activation of ER, and the BIG3-PHB2 interaction target inhibitor peptide (ERAP: BIG3 protein).
- the estrogen (E2)-dependent breast cancer cell growth inhibitory effect by the amino acid sequence from 165th position to 177th position has been clarified (Patent Document 1, WO2017/126461).
- ERAP acts as an inhibitor of interaction by binding to PHB2, but PHB2 is expressed in human whole body organs, thus denying expression of non-selective effects in organs other than cancer tissues. I can't.
- the present inventors have found a PHB2-derived peptide that inhibits the BIG3-PHB2 interaction and exerts an antitumor effect against E2-dependent breast cancer and triple negative breast cancer, and completed the present invention. That is, the present invention provides the following peptides and their uses.
- FIG. 3 shows a schematic diagram of branched and cyclic PHB2 peptides.
- A Linear bond type PHB2 peptide.
- B Branched PHB2 peptide.
- C Cyclic PHB2 peptide.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19890179.5A EP3889264A4 (en) | 2018-11-30 | 2019-11-28 | BREAST CANCER THERAPEUTIC WITH BIG3-PHB2 INTERACTION INHIBITING PEPTIDE FROM PHB2 |
| US17/297,986 US12595289B2 (en) | 2018-11-30 | 2019-11-28 | Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2 |
| JP2020557810A JP7525855B2 (ja) | 2018-11-30 | 2019-11-28 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
| JP2024005446A JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
| US19/546,792 US20260234205A1 (en) | 2018-11-30 | 2026-02-23 | Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2 |
| US19/546,921 US20260209292A1 (en) | 2018-11-30 | 2026-02-23 | Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018225660 | 2018-11-30 | ||
| JP2018-225660 | 2018-11-30 |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/297,986 A-371-Of-International US12595289B2 (en) | 2018-11-30 | 2019-11-28 | Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2 |
| US19/546,792 Continuation US20260234205A1 (en) | 2018-11-30 | 2026-02-23 | Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2 |
| US19/546,921 Continuation US20260209292A1 (en) | 2018-11-30 | 2026-02-23 | Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020111167A1 true WO2020111167A1 (ja) | 2020-06-04 |
Family
ID=70853835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2019/046505 Ceased WO2020111167A1 (ja) | 2018-11-30 | 2019-11-28 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US12595289B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3889264A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7525855B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020111167A1 (cg-RX-API-DMAC7.html) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722858A (en) | 1985-07-01 | 1988-02-02 | Du Pont Canada Inc. | Fire-retardant sheet material |
| US5580895A (en) | 1992-01-21 | 1996-12-03 | Glaxo Spa | 1,5-benzodiazepine derivatives |
| US5589466A (en) | 1989-03-21 | 1996-12-31 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| WO1997016171A1 (fr) | 1995-11-01 | 1997-05-09 | Dnavec Research Inc. | Liposome a membrane fusible faisant appel a un virus sendai recombinant |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| WO1999067288A1 (en) | 1998-06-25 | 1999-12-29 | Sumitomo Pharmaceuticals Company, Limited | Tumor antigen peptides originating in cyclophilin b |
| WO2013018690A1 (ja) * | 2011-07-29 | 2013-02-07 | 国立大学法人徳島大学 | Erap1由来ペプチド及びその使用 |
| WO2017126461A1 (ja) | 2016-01-19 | 2017-07-27 | 国立大学法人徳島大学 | がん治療用ペプチド及びそれを含む医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| JP5339291B2 (ja) | 2006-08-10 | 2013-11-13 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
| CN111148752B (zh) | 2017-07-19 | 2024-01-16 | 国立大学法人德岛大学 | 肽衍生物和包含其的药物组合物 |
-
2019
- 2019-11-28 JP JP2020557810A patent/JP7525855B2/ja active Active
- 2019-11-28 EP EP19890179.5A patent/EP3889264A4/en active Pending
- 2019-11-28 US US17/297,986 patent/US12595289B2/en active Active
- 2019-11-28 WO PCT/JP2019/046505 patent/WO2020111167A1/ja not_active Ceased
-
2024
- 2024-01-17 JP JP2024005446A patent/JP7726464B2/ja active Active
-
2026
- 2026-02-23 US US19/546,921 patent/US20260209292A1/en active Pending
- 2026-02-23 US US19/546,792 patent/US20260234205A1/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722858A (en) | 1985-07-01 | 1988-02-02 | Du Pont Canada Inc. | Fire-retardant sheet material |
| US5589466A (en) | 1989-03-21 | 1996-12-31 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US5580895A (en) | 1992-01-21 | 1996-12-03 | Glaxo Spa | 1,5-benzodiazepine derivatives |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| WO1997016171A1 (fr) | 1995-11-01 | 1997-05-09 | Dnavec Research Inc. | Liposome a membrane fusible faisant appel a un virus sendai recombinant |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| WO1999067288A1 (en) | 1998-06-25 | 1999-12-29 | Sumitomo Pharmaceuticals Company, Limited | Tumor antigen peptides originating in cyclophilin b |
| WO2013018690A1 (ja) * | 2011-07-29 | 2013-02-07 | 国立大学法人徳島大学 | Erap1由来ペプチド及びその使用 |
| WO2017126461A1 (ja) | 2016-01-19 | 2017-07-27 | 国立大学法人徳島大学 | がん治療用ペプチド及びそれを含む医薬組成物 |
Non-Patent Citations (61)
| Title |
|---|
| "Basics and Experiment of Peptide Synthesis", 1985, MARUZEN CO. |
| "GenBank", Database accession no. NM_001267700.1 |
| "Peptide Synthesis", 1975, INTERSCIENCE |
| "peptide synthesis", vol. 14, 1991, article "Development of Pharmaceuticals" |
| "The Proteins", vol. 2, 1976, ACADEMIC PRESS |
| BARANY G.MERRIFIELD R.B.: "Solid Phase Peptide Synthesis", vol. 2, 1980, ACADEMIC PRESS, article "Peptides", pages: 100 - 118 |
| BEAUCAGE SLIYER RP, TETRAHEDRON, vol. 48, 1992, pages 2223 - 311 |
| BETTER ET AL., SCIENCE, vol. 240, no. 4855, 1988, pages 1041 - 3 |
| CHLEBOWSKI, R. ET AL., BREAST, vol. 2, 2009, pages 1 - 11 |
| CHUMSRI, S. ET AL., J. STEROID BIOCHEM. MOL. BIOL., vol. 125, no. 1-2, 2011, pages 13 - 22 |
| CLARK-CURTISSCURTISS ET AL.: "Methods in Enzymology", vol. 101, 1983, pages: 347 - 62 |
| CLARKE, R. ET AL., PHARMACOL. REV., vol. 53, no. 1, 2001, pages 25 - 71 |
| COOS VERHOEF ET AL., EUR. J. DRUG METAB. PHARMACOKIN., vol. 11, no. 4, 1986, pages 291 - 302 |
| CREIGHTON, PROTEINS, 1984 |
| DALBADIE-MCFARLAND ET AL., PROC NATL ACAD SCI USA, vol. 79, no. 21, 1982, pages 6409 - 13 |
| DEROSSI ET AL., J. BIOL. CHEM., vol. 269, no. 14, 1994, pages 10444 - 50 |
| ELMQUIST ET AL., EXP. CELL RES., vol. 269, no. 2, 2001, pages 237 - 44 |
| FASEB J, vol. 6, no. 7, 1992, pages 2422 - 7 |
| FISHER, B. ET AL., J. NATL. CANCER INST., vol. 93, no. 9, 2001, pages 684 - 90 |
| FISHER, B. ET AL., J. NATL. CANCER INST., vol. 97, no. 22, 2005, pages 1652 - 62 |
| GAO ET AL., BIOORG. MED. CHEM., vol. 10, no. 12, 2002, pages 4057 - 65 |
| GREENLOEWENSTEIN, CELL, vol. 55, no. 6, 1988, pages 1179 - 88 |
| HIPP ET AL., IN VIVO, vol. 14, no. 5, 2000, pages 571 - 85 |
| HONGCLAYMAN, CANCER RES., vol. 60, no. 23, 2000, pages 6551 - 6 |
| HOPP ET AL., BIO/TECHNOLOGY, vol. 6, 1988, pages 1204 - 10 |
| JOHNSTON, S. R., CLIN. CANCER RES., vol. 16, no. 7, 2010, pages 1979 - 87 |
| JOLIOT A.PROCHIANTZ A., NAT CELL BIOL., vol. 6, 2004, pages 189 - 96 |
| JORDAN, V. C., NATURE REV. DRUG DISCOV., vol. 2, no. 3, 2003, pages 205 - 13 |
| KASASHIMA K, J BIOL CHEM, vol. 281, no. 47, 2006, pages 36401 - 10 |
| KIM JWAKIYAMA MPARK JH ET AL., CANCER SCI., vol. 100, no. 8, 2009, pages 1468 - 78 |
| LEI ET AL., J BACTERIOL, vol. 169, no. 9, 1987, pages 4379 - 83 |
| LIN ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14255 - 8 |
| LUNDBERG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 299, no. 1, 2002, pages 85 - 90 |
| MARK ET AL., PROC NATL ACAD SCI USA, vol. 81, no. 18, 1984, pages 5662 - 6 |
| MARQUEZ-GARBAN DC ET AL., STEROIDS, vol. 72, no. 2, 2007, pages 135 - 43 |
| MATSUSHITA ET AL., J. NEUROSCI., vol. 21, no. 16, 2003, pages 6000 - 7 |
| MATTHES ET AL., EMBO J, vol. 3, no. 4, 1984, pages 801 - 5 |
| MIZUSHIMA ET AL., NUCLEIC ACIDS RES, vol. 18, no. 17, 1990, pages 5322 |
| MONTANO MM ET AL., PROC NATL ACAD SCI USA., vol. 96, no. 12, 1999, pages 6947 - 52 |
| MORRIS ET AL., NATURE BIOTECHNOL., vol. 19, no. 2, 2001, pages 1173 - 6 |
| MORRISON J, J BACTERIOLOGY, vol. 132, no. 1, 1977, pages 349 - 51 |
| MULLIGAN ET AL., NATURE, vol. 277, no. 5692, 1979, pages 108 - 14 |
| NELLES JL ET AL., EXPERT REV ENDOCRINOL METAB., vol. 6, no. 3, 2011, pages 437 - 51 |
| OEHLKE ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1414, no. 1-2, 1998, pages 127 - 39 |
| PARK ET AL., PROC. NATL ACAD. SCI. USA, vol. 97, no. 15, 2000, pages 8245 - 50 |
| POOGA ET AL., FASEB J., vol. 12, no. 1, 1998, pages 67 - 77 |
| ROUSSELLE ET AL., MOL. PHARMACOL., vol. 57, no. 4, 2000, pages 679 - 86 |
| SAWADA ET AL., NATURE CELL BIOL., vol. 5, no. 4, 2003, pages 352 - 7 |
| SHATA ET AL., MOL MED TODAY, vol. 6, no. 2, 2000, pages 66 - 71 |
| SHEDLOCK ET AL., J LEUKOC BIOL, vol. 68, no. 6, 2000, pages 793 - 806 |
| STABILE LP ET AL., CANCER RES., vol. 65, no. 4, 2005, pages 1459 - 70 |
| STOVER ET AL., NATURE, vol. 351, no. 6326, 1991, pages 456 - 60 |
| THOMAS KRCAPECCHI MR, CELL, vol. 51, no. 3, 1987, pages 503 - 12 |
| WARD ET AL., NATURE, vol. 341, no. 6242, 1989, pages 544 - 6 |
| WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 8 |
| YI-AN CHEN;YOICHI MURAKAMI;SHANDAR AHMAD;TETSURO YOSHIMARU;TOYOMASA KATAGIRI;KENJI MIZUGUCHI: "Brefeldin A-inhibited guanine nucleotide-exchange protein 3(BIG3) is predicted to interact with its partner through an ARM-type a-helical structure", BMC RESEARCH NOTES, vol. 7, 435, 6 July 2014 (2014-07-06), pages 1 - 8, XP021191174, ISSN: 1756-0500, DOI: 10.1186/1756-0500-7-435 * |
| YOSHIMARU TETSURO : "2P-0632: A-kinase anchoring protein BIG3-PHB2axis is required for progression of HER2-rich breastcancer cells", 41ST ANNUAL MEETING OF THE MOLECULAR BIOLOGY SOCIETY OF JAPAN; NOVEMBER 28-30, 2018, vol. 41, 9 November 2018 (2018-11-09), JP, XP009528043 * |
| YOSHIMARU, T. ET AL., NAT. COMMUN., vol. 4, 2013, pages 2443 |
| YOSHIMARU, T. ET AL., SCI REP., vol. 7, no. 1, 2017, pages 1821 |
| YUBA E ET AL., J. CONTROL. RELEASE, vol. 149, 2011, pages 72 - 80 |
| ZOLLERSMITH, NUCLEIC ACIDS RES, vol. 10, no. 20, 1982, pages 6487 - 500 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220098256A1 (en) | 2022-03-31 |
| JP7726464B2 (ja) | 2025-08-20 |
| JP7525855B2 (ja) | 2024-07-31 |
| US20260209292A1 (en) | 2026-07-23 |
| US12595289B2 (en) | 2026-04-07 |
| EP3889264A1 (en) | 2021-10-06 |
| JPWO2020111167A1 (ja) | 2021-10-28 |
| JP2024045244A (ja) | 2024-04-02 |
| EP3889264A4 (en) | 2022-10-12 |
| US20260234205A1 (en) | 2026-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11884708B2 (en) | Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs | |
| JP6014904B2 (ja) | Erap1由来ペプチド及びその使用 | |
| US10087215B2 (en) | Stabilized SOS1 peptides | |
| WO2004092339A2 (en) | Modulation of muc1 mediated signal transduction | |
| EP3066113A2 (en) | Peptide inhibitors of tead/yap-taz interaction | |
| AU2022203604A1 (en) | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | |
| IL275774A (en) | Variants of ATF5 peptide and their uses | |
| US10106590B2 (en) | BH4 stabilized peptides and uses thereof | |
| CN101146822A (zh) | EphB受体结合肽 | |
| JP2024028553A (ja) | Dpep-1結合剤および使用の方法 | |
| WO2014142619A1 (ko) | Aimp2-dx2와 pl4/arf의 상호작용을 이용한 암 치료제의 스크리닝 방법 | |
| CN115397513A (zh) | 改进的抗衰老化合物及其用途 | |
| IL295634A (en) | Molecules targeting ras protein | |
| JP7525855B2 (ja) | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 | |
| US10907212B2 (en) | Inhibitors of cell adhesion | |
| Crnković-Mertens et al. | Isolation of peptides blocking the function of anti-apoptotic Livin protein | |
| CN111148752A (zh) | 肽衍生物和包含其的药物组合物 | |
| US12552834B2 (en) | Selective MENA binding peptides | |
| Hansen et al. | Identification of Amino Acid Residues in PEPHC1 Important for Binding to the Tumor‐Specific Receptor EGFRvIII | |
| EP2392585A2 (en) | Scaffold proteins for recombinant peptide aptamers | |
| KR20250138134A (ko) | 표적 단백질 분해자 및 세포 투과 펩타이드를 포함하는 융합 분자 및 이의 용도 | |
| Afrose | Influence of Single and Multiple Histidine Residues and Their Ionization Properties on Transmembrane Helix Dynamics, Orientations and Fraying | |
| Wen | Development and Application of Cell Penetrating Beta-Hairpin and Alpha-Helical Peptides | |
| Quach | Investigating the Factors that Affect Trafficking of Hydrocarbon-Stapled Peptides and the Epidermal Growth Factor Receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19890179 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2020557810 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2019890179 Country of ref document: EP Effective date: 20210630 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 17297986 Country of ref document: US |